Geneart AG

Geneart AG (OJ:G6A) - GENEART presents the advantages of designed genes and gene synthesis in the programming of vaccines - GENEART will chair an "Industrial Biotechnology" workshop - 'Synthetic Biology 4.0' is the most important international conference on Synthetic Biology, now in its fourth year - GENEART is one of the main sponsors - With DNA synthesis, GENEART provides one of the key technologies for the Synthetic Biology

Geneart AG (OJ:G6A) - The iGEM ("International Genetically Engineered Machine") competition is the only competition of its kind. Its objective is the development of standardized DNA components for applications in Synthetic Biology - GENEART is sponsoring partner of this competition, supporting the organizers and the student teams and donating one of the main prizes - 84 Teams of students from all corners of the globe participate

Geneart AG (OJ:G6A) - GENEART increases sales activities in its key foreign market - Founding of a new sales office in San Francisco (California, USA) is completed - GENEART positions itself in the vicinity of customers on the west coast, with research budgets of more than USD 12 billion

Geneart AG (OJ:G6A) - Optimized synthetic standard genes are now also available for use in insect or mammalian cells

- The Deutsche Messe AG in Hannover (Germany) ranks the GENEART AG as one of the best European enterprises in biotechnology and life sciences - The exceptional innovative spirit combined with a high-performance business concept qualified the GENEART AG team for the final - The renowned biotechnology prize will be awarded on October 06, 2008 in Hannover